Location Directory

Clinical trials in Pittsburgh, Pennsylvania

This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:19 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10624

Shown on this page

Current sort

Institutions in Pittsburgh

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UPMC (University of Pittsburgh)

Live official records

Open in full search

Conditions: Idiopathic Inflammatory Myopathies
Interventions: Placebo, Nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 18 more

Conditions: Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Interventions: Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Malignant Solid Neoplasm
Interventions: Best Practice, Financial Navigation, Interview, Survey Administration; Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: Not listed
Enrollment: 760 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 383
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 252 more

Conditions: Obesity
Interventions: survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 5,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 153
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more

Conditions: Retinitis Pigmentosa, Eye Diseases
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 13
States / cities: San Francisco, California • Denver, Colorado • Gainesville, Florida + 10 more

Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 4 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Interventions: JANX007, Darolutamide; Biological · Drug
Lead sponsor: Janux Therapeutics; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Type 2 Diabetes
Interventions: Placebo, Survodutide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 65 more

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions: STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin; Drug
Lead sponsor: Synthekine; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 35
States / cities: Tucson, Arizona • Beverly Hills, California • Fullerton, California + 28 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: MPowerHub, Continuous Glucose Monitor (CGM), Activity Monitor; Device
Lead sponsor: Ann-Marie Rosland; Other
Eligibility: 25 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions: Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 124
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more

Conditions: Solid Tumors, Hematologic Malignancies
Interventions: Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 65
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more

Clinical trials in Pittsburgh, Pennsylvania

Filter and sort this location

Institutions in Pittsburgh

Live official records

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Rate of Progression in EYS Related Retinal Degeneration

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)